You are here
ARCHER PHARMACEUTICALS, INC.
UEI: F8JZB7RBLFR6
# of Employees: 0
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.
Amount: $1,511,397.00Pathological hallmarks of Alzheimerandapos;s disease (AD) include extracellular deposits of Aβ peptides, intraneuronal aggregates of abnormally phosphorylated tau protein and neuroinflammation. Most ...
STTRPhase II2020Department of Health and Human Services National Institutes of Health -
Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.
Amount: $224,920.00Pathological hallmarks of Alzheimerandapos s diseaseADinclude extracellular deposits of Apeptidesintraneuronal aggregates of abnormally phosphorylated tau protein and neuroinflammationMost proposed AD ...
STTRPhase I2018Department of Health and Human Services National Institutes of Health -
Pre-clinical Development of a Therapeutic for Alzheimer's Disease
Amount: $150,000.00DESCRIPTION (provided by applicant): The A2 peptide is widely thought to be implicated in the pathogenesis of Alzheimer's Disease (AD) and A2-lowering strategies are being pursued by most maj ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health